Cargando…
Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/TNFSF10/Apo2L) holds promise for cancer therapy as it induces apoptosis in a large variety of cancer cells while exerting negligible toxicity in normal ones. However, TRAIL can also induce proliferative and migratory signaling in cancer...
Autores principales: | Pavet, V, Shlyakhtina, Y, He, T, Ceschin, D G, Kohonen, P, Perälä, M, Kallioniemi, O, Gronemeyer, H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040674/ https://www.ncbi.nlm.nih.gov/pubmed/24481457 http://dx.doi.org/10.1038/cddis.2014.5 |
Ejemplares similares
-
Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells
por: Shlyakhtina, Yelyzaveta, et al.
Publicado: (2017) -
Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis
por: Lee, Ji-Hye, et al.
Publicado: (2014) -
In silico docking of urokinase plasminogen activator and integrins
por: Degryse, Bernard, et al.
Publicado: (2008) -
Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017) -
Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
por: Zhu, Ran, et al.
Publicado: (2022)